• Amey Dhananjay Kadam
• Omkar soni
• Harshavardhan Sature
• Prof.Akash jadhav
• Dr. Vivekkumar Redasani

Glimepiride, a third-generation sulfonylurea, is a widely prescribed antidiabetic agent in India due to its efficacy, cost-effectiveness, and favorable safety profile. With India being the "diabetes capital of the world," the demand for effective oral hypoglycemic agents (OHAs) continues to rise. This review provides an updated and comprehensive market analysis of glimepiride in India, covering sales trends, competitive landscape, pricing dynamics, regulatory environment, and emerging opportunities. The study incorporates the latest data (2023–2024) from pharmaceutical sales reports, government health policies, and clinical prescription trends. The findings highlight glimepiride’s sustained market dominance despite competition from newer drug classes, emphasizing its role in India’s diabetes management ecosystem.

Keywords – Glimepiride, Sulfonylurea, Antidiabetic agent, India, Oral Hypoglycemic Agents (OHAs), Market analysis, Diabetes management, Sales trends, Competitive landscape

"Market Analysis of Glimepiride as Antidiabetic Agent in India", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 5, page no.l277-l281, May-2025, Available :http://www.jetir.org/papers/JETIR2505C16.pdf

"Market Analysis of Glimepiride as Antidiabetic Agent in India", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 5, page no. ppl277-l281, May-2025, Available at : http://www.jetir.org/papers/JETIR2505C16.pdf